All In Biotech

Drug Trial Radar · NCT01762839

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Dec 27, 2012

Primary completion

Jan 2013

Study completion Feb 11, 2013

Sponsor

Lead sponsor
Melinta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study was to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 milligrams (mg).

Conditions

  • Healthy

Interventions

  • Single-Dose IV Oritavancin DiphosphateDrug

    Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.

  • PlaceboDrug

    Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.

  • MoxifloxacinDrug

    Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Placebo-adjusted change from Baseline in QTcFTime frame: predose, 3,3.5,4,5,6,7,9,11,15,24 hours post infusion start time

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Spaulding Clinical

    West Bend, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.